Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Psyched Wellness ( (TSE:PSYC) ) has provided an update.
Psyched Wellness has announced a series of corporate updates, including the initiation of a Genotoxicity Study on its proprietary Amanita Muscaria Extract (AME-1) to ensure its safety as a dietary supplement. The company has also completed a production run for its products, AME-1 and Calm, to meet online and retail demand, and is working on securing a long-term manufacturing agreement. Strategic partnerships, such as with Zerkalo LLC, are progressing in the development of new dietary supplements, and the company is expanding its route-to-market partnerships nationwide.
More about Psyched Wellness
Psyched Wellness Ltd. is a life sciences company that focuses on the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom.
YTD Price Performance: 20.0%
Average Trading Volume: 67,958
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.99M
For an in-depth examination of PSYC stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue